Highlights of This Issue 2193

SPECIAL FEATURES

CCR 20th Anniversary Commentary

2195 CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio
Susan E. Bates, Robert W. Robey, and Richard L. Piekaz

2198 CCR 20th Anniversary Commentary: Vorinostat—Gateway to Epigenetic Therapy
Wm. Kevin Kelly, Paul Marks, and Victoria M. Richon

CCR Translations

2201 A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2
Yanping Xiao and Gordon J. Freeman
See related article, p. 2359

2204 Diffuse Large B-cell Lymphoma Classification Tied Up Nicely with a "String"
Lisa M. Rimsza
See related article, p. 2367

Molecular Pathways

2207 Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells
Hiba Ahmad Zahreddine and Katherine L.B. Borden

CCR Focus

2212 Quit Early, Quit Often
Susan E. Bates

2213 Lung Cancer in the Era of Precision Medicine
Katerina Politi and Roy S. Herbst

2221 EGFR: The Paradigm of an Oncogene-Driven Lung Cancer
Gregory J. Riely and Helena A. Yu

2227 Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
Ryohei Katayama, Christine M. Lovly, and Alice T. Shaw

2236 Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics
David R. Gandara, Peter S. Hammerman, Martin L. Sos, Primo N. Lara Jr, and Fred R. Hirsch

2244 Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?
M. Catherine Pietanza, Lauren Averett Byers, John D. Minna, and Charles M. Rudin

2256 Immune Checkpoint Modulation for Non–Small Cell Lung Cancer
Jean-Charles Soria, Aurelien Marabelle, Julie R. Brahmer, and Scott Gettinger

Special Report

2263 Accelerating the Delivery of Patient-Centered, High-Quality Cancer Care
Edward Abrahams, Margaret Foti, and Marcia A. Kean

CANCER THERAPY: CLINICAL

2268 Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer

2278 Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma

iv
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation
Martijn P. Lolkema, Hilde H. Bohets, Hendrik-Tobias Arkenau, Ann Lampo, Erio Barale, Maja J.A. de Jonge, Leni van Doorn, Peter Hellemans, Johann S. de Bono, and Ferry A.L.M. Eskens

Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial
Lawrence G. Lum, Archana Thakur, Zaid Al-Kadhimi, Gerald A. Colvin, Francis J. Cummings, Robert D. Legare, Don S. Dixon, Nicola Kouttab, Abby Maizel, William Colaiace, Qin Liu, and Ritesh Rathore

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms
Michele Cioffi, Sara Trabulo, Manuel Hidalgo, Eithne Costello, William Greenhalf, Mert Ezkan, Joerg Kleef, Bruno Sainz Jr, and Christopher Heeschen

Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation
Masanori Hasegawa, Raj Kumar Sinha, Manoj Kumar, Maroof Alam, Li Yin, Deepak Raina, Akriti Kharbanda, Govind Panchamoorthy, Diksho Gupta, Harpal Singh, Surender Kharbanda, and Donald Kufe

Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL
Matthew C. Stubbs, Wonil Kim, Megan Bariteau, Tina Davis, Srithar Vempati, Janna Minehart, Matthew Witkin, Jun Qi, Andrei V. Krivtsov, James E. Bradner, Andrew I. Kung, and Scott A. Armstrong

Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein
Murali Janakiram, Jordan M. Chinai, Susan Fineberg, Andras Fiser, Cristina Montagna, Ramadevi Medavarapu, Ekaterina Castano, Hyungjun Jeon, Kim C. Ohaegbulam, Ruihua Zhao, Aimin Zhao, Steven C. Almo, Joseph A. Sparano, and Xingxing Zang

Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non–Small Cell Lung Cancer
Ahnah Song, Tae Min Kim, Dong-Wan Kim, Soyeon Kim, Bhumsuk Keam, Se-Hoon Lee, and Dae Seog Heo

Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects
Jasmin Wellbrock, Emily Latuske, Julian Köhler, Katharina Wagner, Hauke Stamm, Elke Vettorazzi, Gabi Vohwinkel, Marianne Klokov, Roswitha Uibeileisen, Patrick Ehm, Kristoffer Riecken, Sonja Loges, Felicitas Thol, Claudia Schubert, Michael Amling, Manfred Jäcker, Carsten Bokemeyer, Michael Heuser, Jürgen Krauter, and Walter Fiedler

miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma
Yijun Yang, Fei Li, Manujendra N. Saha, Jahangir Abdí, Lugui Qiu, and Hong Chang

Correction: Ceritinib for the Treatment of Late-Stage (Metastatic) Non–Small Cell Lung Cancer

CORRECTION
2412 Correction: Ceritinib for the Treatment of Late-Stage (Metastatic) Non–Small Cell Lung Cancer
ABOUT THE COVER

The cover shows a section of a bone marrow biopsy from a patient with acute myeloid leukemia (AML). Immunohistochemical staining shows Desert Hedgehog positive osteoblasts underlining the hypothesis of paracrine Hedgehog pathway activation in AML cells. For details, see the article by Wellbrock and colleagues on page 2388 of this issue.